• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Monday

    3/6/23 1:37:08 PM ET
    $AADI
    $ACRS
    $AMRX
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AADI alert in real time by email

     

    On Monday, 36 companies set new 52-week lows.

    Noteworthy Mentions In Today's 52-Week Lows:

    • The largest company by market cap to hit a new 52-week low was Sirius XM Holdings (NASDAQ:SIRI).
    • The smallest company by market cap to set a new 52-week low was Altamira Therapeutics (NASDAQ:CYTO).
    • China Pharma Holding (AMEX:CPHI) saw the most significant move of the companies, as shares traded down 871.52% to reach its new 52-week low.
    • VEON (NASDAQ:VEON) shares rebounded the highest, with shares trading up 0.0%, bouncing back after reaching its new 52-week low.

    Stocks dropping to new 52-week lows on Monday:

    • Sirius XM Holdings (NASDAQ:SIRI) shares fell to $4.20 on Monday, setting a new 52-week low with a shift of down 0.35%.
    • Centrais Eletricas (NYSE:EBR) shares hit a yearly low of $6.26. The stock was down 1.1% on the session.
    • Cosan (NYSE:CSAN) stock achieved a new 52-week low on Monday morning, hitting $11.14 and moving up 0.09%.
    • Equity Commonwealth (NYSE:EQC) shares were down 0.12% for the day, having made a 52-week low of $20.53.
    • VEON (NASDAQ:VEON) stock broke to a new 52-week low of $0.68 on Monday. Shares of the company traded 0.0% (flat).
    • National Healthcare (AMEX:NHC) shares hit a yearly low of $54.76. The stock was up 0.16% on the session.
    • Aclaris Therapeutics (NASDAQ:ACRS) stock hit a yearly low of $5.77. The stock was down 52.03% for the day.
    • Greystone Housing Impact (NYSE:GHI) shares reached a new 52-week low of $17.05 on Monday morning, moving down 2.4%.
    • Guaranty Bancshares (NASDAQ:GNTY) shares set a new 52-week low of $30.51. The stock traded down 0.88%.
    • Surmodics (NASDAQ:SRDX) shares set a new 52-week low of $19.77. The stock traded down 4.73%.
    • Bright Health Gr (NYSE:BHG) shares reached a new 52-week low of $0.43 on Monday morning, moving down 0.04%.
    • Amneal Pharmaceuticals (NYSE:AMRX) shares moved down 3.65% on Monday to hit a new 52-week low of $1.81, drifting down 3.65%.
    • enCore Energy (AMEX:EU) shares fell to $2.20 on Monday, setting a new 52-week low with a shift of down 1.32%.
    • Franklin Street Props (AMEX:FSP) stock hit $2.19 on Monday morning, setting a new 52-week low for a change of down 3.31%.
    • Kinnate Biopharma (NASDAQ:KNTE) shares were down 4.7% for the day, having made a 52-week low of $4.71.
    • Aadi Bioscience (NASDAQ:AADI) stock achieved a new 52-week low on Monday morning, hitting $8.89 and moving down 3.97%.
    • Azure Power Global (NYSE:AZRE) shares were down 12.46% for the day, having made a 52-week low of $2.66.
    • Universal Electronics (NASDAQ:UEIC) stock drifted down 2.51% on Monday morning to hit a new 52-week low of $11.53.
    • Cepton (NASDAQ:CPTN) shares set a new 52-week low of $0.86. The stock traded down 7.63%.
    • Intercure (NASDAQ:INCR) shares were down 6.32% for the day, having made a 52-week low of $2.37.
    • Solid Biosciences (NASDAQ:SLDB) shares reached a new 52-week low of $5.14 on Monday morning, moving down 1.7%.
    • AERWINS Technologies (NASDAQ:AWIN) stock set a new 52-week low of $1.00 on Monday, moving down 12.5%.
    • Evaxion Biotech (NASDAQ:EVAX) stock broke to a new 52-week low of $1.18 on Monday. Shares of the company traded down 6.79%.
    • China Pharma Holding (AMEX:CPHI) shares hit a yearly low of $0.57. The stock was up 871.52% on the session.
    • CN Energy Group (NASDAQ:CNEY) shares reached a new 52-week low of $0.28 on Monday morning, moving down 1.99%.
    • Inpixon (NASDAQ:INPX) stock hit a yearly low of $0.81. The stock was down 7.34% for the day.
    • Jupiter Wellness (NASDAQ:JUPW) stock hit a yearly low of $0.41. The stock was down 1.7% for the day.
    • Aptorum Gr (NASDAQ:APM) stock dropped to a yearly low on Monday of $3.08. Shares traded down 12.25%.
    • Rubius Therapeutics (NASDAQ:RUBY) stock set a new 52-week low of $0.09 on Monday, moving down 22.26%.
    • Panbela Therapeutics (NASDAQ:PBLA) shares made a new 52-week low of $0.89 on Monday. The stock was down 2.42% for the day.
    • Petros Pharmaceuticals (NASDAQ:PTPI) stock broke to a new 52-week low of $1.71 on Monday. Shares of the company traded up 3.26%.
    • Kalera (NASDAQ:KAL) shares reached a new 52-week low of $4.10 on Monday morning, moving down 2.79%.
    • Altamira Therapeutics (NASDAQ:CYTO) shares hit a yearly low of $2.03. The stock was down 13.11% on the session.

    Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. Click here to learn more.

    Get the next $AADI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AADI
    $ACRS
    $AMRX
    $APM

    CompanyDatePrice TargetRatingAnalyst
    SiriusXM Holdings Inc.
    $SIRI
    4/23/2026$46.00Neutral → Buy
    Rosenblatt
    Amneal Pharmaceuticals Inc.
    $AMRX
    4/17/2026$19.00Buy
    UBS
    VEON Ltd. ADS
    $VEON
    4/16/2026$74.00Buy
    Rothschild & Co Redburn
    Aclaris Therapeutics Inc.
    $ACRS
    4/16/2026$10.00Outperform
    Oppenheimer
    Solid Biosciences Inc.
    $SLDB
    3/20/2026$26.00Buy
    Guggenheim
    Evaxion A/S
    $EVAX
    2/19/2026$10.00Buy
    Maxim Group
    SiriusXM Holdings Inc.
    $SIRI
    2/10/2026$24.00Underweight → Neutral
    Analyst
    SiriusXM Holdings Inc.
    $SIRI
    2/6/2026Buy → Neutral
    Seaport Research Partners
    More analyst ratings

    $AADI
    $ACRS
    $AMRX
    $APM
    SEC Filings

    View All

    SEC Form DEFA14A filed by Amneal Pharmaceuticals Inc.

    DEFA14A - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)

    4/23/26 4:18:56 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by VEON Ltd. ADS

    6-K - VEON Ltd. (0001468091) (Filer)

    4/23/26 4:17:58 PM ET
    $VEON
    Telecommunications Equipment
    Telecommunications

    SEC Form DEFA14A filed by Solid Biosciences Inc.

    DEFA14A - Solid Biosciences Inc. (0001707502) (Filer)

    4/23/26 4:07:44 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AADI
    $ACRS
    $AMRX
    $APM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sirius XM upgraded by Rosenblatt with a new price target

    Rosenblatt upgraded Sirius XM from Neutral to Buy and set a new price target of $46.00

    4/23/26 7:45:40 AM ET
    $SIRI
    Broadcasting
    Consumer Discretionary

    UBS initiated coverage on Amneal Pharmaceuticals with a new price target

    UBS initiated coverage of Amneal Pharmaceuticals with a rating of Buy and set a new price target of $19.00

    4/17/26 8:10:24 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rothschild & Co Redburn initiated coverage on VEON with a new price target

    Rothschild & Co Redburn initiated coverage of VEON with a rating of Buy and set a new price target of $74.00

    4/16/26 8:05:08 AM ET
    $VEON
    Telecommunications Equipment
    Telecommunications

    $AADI
    $ACRS
    $AMRX
    $APM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chahil Satjiv S bought $60,579 worth of shares (8,935 units at $6.78) (SEC Form 4)

    4 - UNIVERSAL ELECTRONICS INC (0000101984) (Issuer)

    6/9/25 3:12:23 PM ET
    $UEIC
    Consumer Electronics/Appliances
    Consumer Staples

    Director Singer Eric bought $59,114 worth of shares (8,890 units at $6.65), increasing direct ownership by 17% to 61,297 units (SEC Form 4)

    4 - UNIVERSAL ELECTRONICS INC (0000101984) (Issuer)

    6/3/25 6:51:59 PM ET
    $UEIC
    Consumer Electronics/Appliances
    Consumer Staples

    Director Singer Eric bought $47,832 worth of shares (7,000 units at $6.83), increasing direct ownership by 18% to 46,403 units (SEC Form 4)

    4 - UNIVERSAL ELECTRONICS INC (0000101984) (Issuer)

    5/21/25 3:28:34 PM ET
    $UEIC
    Consumer Electronics/Appliances
    Consumer Staples

    $AADI
    $ACRS
    $AMRX
    $APM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    VEON Boosts Accessibility for Investors by Waiving Depositary Service Fees on American Depositary Shares

    Dubai and New York, April 24, 2026 – VEON Ltd. (NASDAQ:VEON), a global digital operator (the "Company" or "VEON"), announces that, effective January 1, 2026, BNY Mellon will not collect depositary service fees ("DSF") from investors that hold VEON's American Depositary Shares ("ADSs"). The suspension of DSF charges for investors effectively reduces the cost of ownership by USD 0.05 per ADS per year and enhances accessibility for both existing and prospective investors. "VEON's steps to reduce the cost of ownership of ADSs and introduce a capital allocation policy that targets to return at least USD 100 million annually through share buybacks are both responses to our ongoing dialogue with i

    4/24/26 2:47:34 AM ET
    $VEON
    Telecommunications Equipment
    Telecommunications

    SiriusXM Declares Quarterly Cash Dividend

    NEW YORK, April 23, 2026 /PRNewswire/ -- SiriusXM (NASDAQ:SIRI) today announced that its Board of Directors declared a quarterly cash dividend of $0.27 per share of common stock. This regular quarterly dividend is payable in cash on May 27, 2026, to stockholders of record at the close of business on May 11, 2026. About Sirius XM Holdings Inc.SiriusXM is the leading audio entertainment company in North America with a portfolio of audio businesses including its flagship subscription entertainment service SiriusXM; the ad-supported and premium music streaming services of Pandora; a

    4/23/26 4:30:00 PM ET
    $SIRI
    Broadcasting
    Consumer Discretionary

    Franklin Street Properties Corp. Announces Expansion of Strategic Alternatives Process

    Franklin Street Properties Corp. (the "Company", "FSP", "our" or "we") (NYSE:FSP), a real estate investment trust (REIT), announced today that it has expanded its ongoing strategic alternatives review process to include BofA Securities and Jones Lang LaSalle Securities, LLC ("JLL Securities") as co-financial advisors in an expansion of its ongoing strategic review process. The expanded process is designed to enhance the Company's ability to evaluate and execute a broad range of potential transactions. BofA Securities and JLL Securities bring complementary capabilities across capital markets, mergers and acquisitions, and asset level execution, positioning the Company to assess opportuniti

    4/23/26 4:21:00 PM ET
    $FSP
    Real Estate Investment Trusts
    Real Estate

    $AADI
    $ACRS
    $AMRX
    $APM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Little Richard H

    4 - enCore Energy Corp. (0001500881) (Issuer)

    4/22/26 4:15:03 PM ET
    $EU
    Other Metals and Minerals
    Basic Materials

    SEC Form 3 filed by new insider Little Richard H

    3 - enCore Energy Corp. (0001500881) (Issuer)

    4/22/26 4:10:04 PM ET
    $EU
    Other Metals and Minerals
    Basic Materials

    SEC Form 3 filed by new insider Sheriff William M

    3 - enCore Energy Corp. (0001500881) (Issuer)

    4/22/26 4:05:08 PM ET
    $EU
    Other Metals and Minerals
    Basic Materials

    $AADI
    $ACRS
    $AMRX
    $APM
    Financials

    Live finance-specific insights

    View All

    SiriusXM Declares Quarterly Cash Dividend

    NEW YORK, April 23, 2026 /PRNewswire/ -- SiriusXM (NASDAQ:SIRI) today announced that its Board of Directors declared a quarterly cash dividend of $0.27 per share of common stock. This regular quarterly dividend is payable in cash on May 27, 2026, to stockholders of record at the close of business on May 11, 2026. About Sirius XM Holdings Inc.SiriusXM is the leading audio entertainment company in North America with a portfolio of audio businesses including its flagship subscription entertainment service SiriusXM; the ad-supported and premium music streaming services of Pandora; a

    4/23/26 4:30:00 PM ET
    $SIRI
    Broadcasting
    Consumer Discretionary

    Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance

    – Acquisition Positions Amneal to Capitalize on $300B+ Global Biologics LOE Opportunity – – Transaction Accelerates Growth Profile and Diversification – – Preliminary Q1 Results Reflect Continued Growth and Raising 2026 Full Year Guidance – – Company to Host Investor Conference Call Today at 8:30 a.m. EST – BRIDGEWATER, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines, today announced that it has entered into a definitive agreement to acquire 100% of Kashiv BioSciences, LLC ("Kashiv") in a transaction w

    4/22/26 6:00:00 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    enCore Energy Appoints Richard Little as Chief Executive Officer; William M. Sheriff Returns as Executive Chair

    NASDAQ:EUTSXV:EUwww.encoreuranium.comDALLAS, April 20, 2026 /CNW/ - enCore Energy Corp. (NASDAQ:EU) (TSXV:EU) (the "Company" or "enCore"), America's Clean Energy Company™, announced today that the independent members of its Board of Directors have unanimously voted to appoint Richard H. Little as Chief Executive Officer, replacing Robert Willette, effective immediately. Mr. Little will also join the Company's Board of Directors, effective immediately. enCore Founder and former Executive Chair, William M. Sheriff, has agreed to the Board's request for his immediate return as Executive Chair.

    4/20/26 7:00:00 AM ET
    $EU
    Other Metals and Minerals
    Basic Materials

    $AADI
    $ACRS
    $AMRX
    $APM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by enCore Energy Corp.

    SC 13G - enCore Energy Corp. (0001500881) (Subject)

    12/11/24 11:30:47 AM ET
    $EU
    Other Metals and Minerals
    Basic Materials

    Amendment: SEC Form SC 13D/A filed by Franklin Street Properties Corp.

    SC 13D/A - FRANKLIN STREET PROPERTIES CORP /MA/ (0001031316) (Subject)

    12/2/24 10:45:14 AM ET
    $FSP
    Real Estate Investment Trusts
    Real Estate

    SEC Form SC 13G filed by Aclaris Therapeutics Inc.

    SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

    11/25/24 11:02:19 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AADI
    $ACRS
    $AMRX
    $APM
    Leadership Updates

    Live Leadership Updates

    View All

    Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson's Awareness Month

    BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ:AMRX) today announced donations totaling $2 million to multiple patient assistance foundations supporting individuals living with Parkinson's disease (PD) in recognition of Parkinson's Awareness Month. These contributions reflect Amneal's ongoing commitment to expanding access to essential medicines and supporting patient care, education, and advocacy for the Parkinson's community. Every six minutes, someone in the United States is diagnosed with Parkinson's disease, underscoring the growing impact of a condition that affects more than 10 million people worldwide. As the

    4/7/26 8:00:00 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VEON Announces 2026 AGM and Board Nominees

    Dubai and New York, March 31, 2026 – VEON Ltd. (NASDAQ:VEON), a global digital operator, ("VEON" or the "Company"), today announced that its Board of Directors (the "Board") has set the date for the Company's 2026 Annual General Meeting of Shareholders (the "AGM") for May 11, 2026 at 12:00 Gulf Standard Time. The record date for the AGM has been set for March 31, 2026. The Board and its Nomination Committee have recommended VEON's seven current Board members for re-election at the AGM. The recommended nominees are Augie K Fabela II, Andrei Gusev, Sir Brandon Lewis, Duncan Perry, the 70th U.S. Secretary of State Michael R. Pompeo, Michiel Soeting, and the Company's Chief Executive Officer Ka

    3/31/26 8:36:29 AM ET
    $VEON
    Telecommunications Equipment
    Telecommunications

    Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

    - Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug (ATI-045) in patients with moderate-to-severe atopic dermatitis (AD). Top line results are expected in the fourth quarter of 2026. "The strong interest in participating in this Phase 2 trial reflects the urgent need for innovative solutions in atopic dermatitis and the excitement surrou

    3/18/26 6:55:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care